MCID: CWD006
MIFTS: 68

Cowden Syndrome 1 malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Gastrointestinal diseases, Skin diseases, Fetal diseases

Aliases & Classifications for Cowden Syndrome 1

About this section
Sources:
2CDC, 11Disease Ontology, 12diseasecard, 13DISEASES, 24GeneTests, 25Genetics Home Reference, 27GTR, 31ICD10 via Orphanet, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot, 71Wikipedia
See all MalaCards sources

Aliases & Descriptions for Cowden Syndrome 1:

Name: Cowden Syndrome 1 52 70 27 12
Cowden Disease 11 48 25 54 70 50 13
Lhermitte-Duclos Disease 11 48 54 70 27 68
Multiple Hamartoma Syndrome 11 48 25 54 70
Cowden Syndrome 71 48 24 25 54
Cs 48 25 70 2
Dysplastic Gangliocytoma of the Cerebellum 48 54 70
Mham 48 25 70
Cd 48 25 70
Cerebelloparenchymal Disorder Vi 70 68
Pten Hamartoma Tumor Syndrome 70 68
Hamartoma Syndrome, Multiple 39 68
 
Cowden's Syndrome 25 27
Cowden's Disease 48 25
Ldd 54 70
Cerebellar Granule Cell Hypertrophy and Megalencephaly 70
Dysplastic Gangliocytoma of Cerebellum 11
Lhermitte-Duclos Syndrome 52
Proteus-Like Syndrome 54
Cohen-Hayden Syndrome 54
Lumbar Disc Disease 68
Phts 70
Cws1 70
Cpd6 70

Characteristics:

Orphanet epidemiological data:

54
cowden disease:
Inheritance: Autosomal dominant; Prevalence: 1-9/1000000 (Netherlands),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age
lhermitte-duclos disease:
Prevalence: <1/1000000 (Worldwide); Age of onset: Adult
proteus-like syndrome:
Inheritance: Autosomal dominant; Age of onset: Infancy,Neonatal

HPO:

64
cowden syndrome 1:
Inheritance: autosomal dominant inheritance
Onset and clinical course: adult onset

Classifications:



External Ids:

OMIM52 158350
Disease Ontology11 DOID:6457
MeSH39 D006223
NCIt45 C3076, C8419
SNOMED-CT62 58037000, 67944007
MESH via Orphanet40 D006223
UMLS via Orphanet69 C0018553, C1866398, C1266181 C0391826, more
ICD10 via Orphanet31 Q85.8, Q87.3, Q04.8

Summaries for Cowden Syndrome 1

About this section
UniProtKB/Swiss-Prot:70 Cowden syndrome 1: An autosomal dominant hamartomatous polyposis syndrome with age- related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. Lhermitte-Duclos disease: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome.

MalaCards based summary: Cowden Syndrome 1, also known as cowden disease, is related to cowden syndrome 6 and familial breast cancer, and has symptoms including abnormality of the tongue, macrocephaly and myopia. An important gene associated with Cowden Syndrome 1 is PTEN (Phosphatase And Tensin Homolog), and among its related pathways are PDGFR-beta signaling pathway and Small cell lung cancer. Affiliated tissues include breast, thyroid and skin, and related mouse phenotypes are Decreased sensitivity to paclitaxel and Increased cell viability after pRB stimulation.

Genetics Home Reference:25 Cowden syndrome is a disorder characterized by multiple noncancerous, tumor-like growths called hamartomas and an increased risk of developing certain cancers.

OMIM:52 Cowden syndrome and Bannayan-Ruvalcaba-Riley syndrome (BRRS; 153480) share clinical characteristics such as... (158350) more...

Disease Ontology:11 An autosomal dominant disease characterized by multiple noncancerous, tumor-like growths (hamartomas) and an increased risk of certain forms of cancer, especially breast, thyroid and endometrium. It is caused by mutations in the PTEN, SDHB, SDHD and KLLN genes.

NIH Rare Diseases:48 Cowden syndrome is an inherited condition that is characterized primarily by multiple, noncancerous growths (called hamartomas) on various parts of the body. People with the syndrome usually have large head (macrocephaly), benign tumors of the hair follicle (trichilemmomas), and white papules with a smooth surface in the mouth (papillomatous papules), starting by the late 20s. It is considered part of the PTEN Hamartoma Tumor Syndrome spectrum which also includes Bannayan-Riley-Ruvalcaba syndrome and Proteus syndrome. People who have Cowden syndrome are at an increased risk of developing certain types of cancer, such as breast, thyroid, and endometrial (lining of the uterus) cancer. Most cases are caused by mutations in the PTEN gene and are inherited in an autosomal dominant manner. Management typically includes screening for associated tumors and/or prophylactic surgeries. Last updated: 1/6/2017

Wikipedia:71 Cowden syndrome (also known as \"Cowden\'s disease,\" and \"multiple hamartoma syndrome\") is a rare... more...

Related Diseases for Cowden Syndrome 1

About this section

Diseases in the Cowden Syndrome 1 family:

Cowden Syndrome 2 Cowden Syndrome 5
Cowden Syndrome 4 Cowden Syndrome 3
Cowden Syndrome 6 Cowden Syndrome 7

Diseases related to Cowden Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 178)
idRelated DiseaseScoreTop Affiliating Genes
1cowden syndrome 633.7AKT1, CDKN3, PIK3CA, PTEN, TNS1
2familial breast cancer30.2BRCA1, BRCA2
3breast cancer29.3AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA
4renal cell carcinoma29.0AKT1, EGFR, KLLN, PIK3CA, PTEN, SDHB
5colorectal cancer28.2AKT1, BRCA1, BRCA2, EGFR, PIK3CA, PTEN
6proteus-like syndrome12.5
7pten hamartoma tumor syndrome12.4
8cowden syndrome 312.2
9cowden syndrome 212.2
10cowden syndrome 512.2
11cowden syndrome 412.2
12cowden syndrome 712.1
13proteus like syndrome mental retardation eye defect12.1
14cockayne syndrome11.6
15xeroderma pigmentosum, group d11.5
16chanarin-dorfman syndrome11.4
17xeroderma pigmentosum, group b11.4
18xeroderma pigmentosum, group g11.4
19xeroderma pigmentosum, group f11.4
20cockayne syndrome, type a11.2
21intervertebral disc disease11.2
22conduct disorder11.1
23oppositional defiant disorder11.1
24proteus syndrome, somatic11.0
25diabetes mellitus, noninsulin-dependent11.0
26cpt deficiency, hepatic, type ii10.9
27cerebral creatine deficiency syndrome 210.9
28cerebral creatine deficiency syndrome10.9
29bartonellosis10.9
30cat-scratch disease10.9
31critical illness polyneuropathy10.9
32mitochondrial cardiomyopathy10.9
33refractory celiac disease10.8
34macular dystrophy, retinal, 1, north carolina type10.8BMPR1A, PTEN
35interstitial myocarditis10.8PIK3CA, PTEN
36chromosome 15q24 deletion syndrome10.8BMPR1A, PTEN
37gastric cancer, somatic10.8
38polyposis, juvenile intestinal10.8
39c syndrome10.7
40crouzon syndrome10.7
41xeroderma pigmentosum-cockayne syndrome complex10.7
42congenital pulmonary veins atresia or stenosis10.7BRCA1, BRCA2
43pancreatitis, pediatric10.7PIK3CA, SDHC, SDHD
44malignant spindle cell melanoma10.7PIK3CA, PTEN, SDHB
45torticollis, familial10.7SDHB, SDHC, SDHD
46neuroendocrine carcinoma of the cervix10.7SDHB, SDHC, SDHD
47tonsil cancer10.7AKT1, EGFR, PTEN
48braf-related leopard syndrome10.7BMPR1A, SMAD4
49carcinoid tumors, intestinal10.7SDHB, SDHC, SDHD
50paraganglioma and gastric stromal sarcoma10.7SDHB, SDHC, SDHD

Graphical network of the top 20 diseases related to Cowden Syndrome 1:



Diseases related to cowden syndrome 1

Symptoms & Phenotypes for Cowden Syndrome 1

About this section

Symptoms by clinical synopsis from OMIM:

158350

Clinical features from OMIM:

158350

Human phenotypes related to Cowden Syndrome 1:

 64 54 (show all 139)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the tongue64 hallmark (90%) HP:0000157
2 macrocephaly64 54 hallmark (90%) Frequent (79-30%) HP:0000256
3 myopia64 54 hallmark (90%) Occasional (29-5%) HP:0000545
4 abnormality of the pupil64 54 hallmark (90%) Very frequent (99-80%) HP:0000615
5 dental malocclusion64 hallmark (90%) HP:0000689
6 melanocytic nevus64 54 hallmark (90%) Frequent (79-30%) HP:0000995
7 epibulbar dermoid64 54 hallmark (90%) Very frequent (99-80%) HP:0001140
8 seizures64 54 hallmark (90%) Occasional (29-5%) HP:0001250
9 foot polydactyly64 hallmark (90%) HP:0001829
10 nausea and vomiting64 54 hallmark (90%) Very frequent (99-80%) HP:0002017
11 migraine64 hallmark (90%) HP:0002076
12 incoordination64 hallmark (90%) HP:0002311
13 increased intracranial pressure64 54 hallmark (90%) Occasional (29-5%) HP:0002516
14 genu recurvatum64 54 hallmark (90%) Very frequent (99-80%) HP:0002816
15 neoplasm of the nervous system64 hallmark (90%) HP:0004375
16 aplasia/hypoplasia of the cerebellum64 hallmark (90%) HP:0007360
17 irregular hyperpigmentation64 54 hallmark (90%) Very frequent (99-80%) HP:0007400
18 arteriovenous malformation64 hallmark (90%) HP:0100026
19 cognitive impairment64 54 hallmark (90%) Frequent (79-30%) HP:0100543
20 lower limb asymmetry64 54 hallmark (90%) Very frequent (99-80%) HP:0100559
21 exostoses64 54 hallmark (90%) Frequent (79-30%) HP:0100777
22 uterine neoplasm64 hallmark (90%) HP:0010784
23 neoplasm of the breast64 hallmark (90%) HP:0100013
24 neoplasm of the thyroid gland64 54 hallmark (90%) Occasional (29-5%) HP:0100031
25 conjunctival hamartoma64 54 hallmark (90%) Very frequent (99-80%) HP:0100780
26 intestinal polyposis64 hallmark (90%) HP:0200008
27 verrucae64 hallmark (90%) HP:0200043
28 mandibular prognathia64 54 typical (50%) Frequent (79-30%) HP:0000303
29 cataract64 54 typical (50%) Occasional (29-5%) HP:0000518
30 retinal detachment64 54 typical (50%) Frequent (79-30%) HP:0000541
31 abnormality of the parathyroid gland64 54 typical (50%) Frequent (79-30%) HP:0000828
32 multiple lipomas64 typical (50%) HP:0001012
33 heterochromia iridis64 54 typical (50%) Frequent (79-30%) HP:0001100
34 communicating hydrocephalus64 54 typical (50%) Frequent (79-30%) HP:0001334
35 venous insufficiency64 54 typical (50%) Frequent (79-30%) HP:0005293
36 shagreen patch64 54 typical (50%) Frequent (79-30%) HP:0009721
37 hyperostosis64 54 typical (50%) Very frequent (99-80%) HP:0100774
38 abnormality of the penis64 54 typical (50%) Frequent (79-30%) HP:0000036
39 abnormality of the teeth64 typical (50%) HP:0000164
40 gingival overgrowth64 typical (50%) HP:0000212
41 furrowed tongue64 54 typical (50%) Frequent (79-30%) HP:0000221
42 dolichocephaly64 54 typical (50%) Occasional (29-5%) HP:0000268
43 goiter64 54 typical (50%) Very frequent (99-80%) HP:0000853
44 palmoplantar keratoderma64 54 typical (50%) Very frequent (99-80%) HP:0000982
45 hypertrichosis64 typical (50%) HP:0000998
46 hypermelanotic macule64 typical (50%) HP:0001034
47 cavernous hemangioma64 54 typical (50%) Frequent (79-30%) HP:0001048
48 anemia64 typical (50%) HP:0001903
49 gastrointestinal hemorrhage64 typical (50%) HP:0002239
50 meningioma64 54 typical (50%) Frequent (79-30%) HP:0002858
51 mucosal telangiectasiae64 54 typical (50%) Frequent (79-30%) HP:0100579
52 intellectual disability64 54 12% Frequent (79-30%) HP:0001249
53 intellectual disability, mild64 12% HP:0001256
54 tall stature64 occasional (7.5%) HP:0000098
55 polycystic ovaries64 54 occasional (7.5%) Occasional (29-5%) HP:0000147
56 anteverted nares64 54 occasional (7.5%) Occasional (29-5%) HP:0000463
57 downslanted palpebral fissures64 54 occasional (7.5%) Occasional (29-5%) HP:0000494
58 splenomegaly64 54 occasional (7.5%) Occasional (29-5%) HP:0001744
59 abnormality of neuronal migration64 occasional (7.5%) HP:0002269
60 skeletal dysplasia64 54 occasional (7.5%) Occasional (29-5%) HP:0002652
61 thymus hyperplasia64 54 occasional (7.5%) Occasional (29-5%) HP:0010516
62 bronchogenic cyst64 54 occasional (7.5%) Occasional (29-5%) HP:0100730
63 abnormality of the palate64 occasional (7.5%) HP:0000174
64 hearing impairment64 54 occasional (7.5%) Occasional (29-5%) HP:0000365
65 autism64 54 occasional (7.5%) Occasional (29-5%) HP:0000717
66 pectus excavatum64 54 occasional (7.5%) Occasional (29-5%) HP:0000767
67 gynecomastia64 54 occasional (7.5%) Occasional (29-5%) HP:0000771
68 cafe-au-lait spot64 occasional (7.5%) HP:0000957
69 hypopigmented skin patches64 54 occasional (7.5%) Occasional (29-5%) HP:0001053
70 brachydactyly syndrome64 54 occasional (7.5%) Occasional (29-5%) HP:0001156
71 scoliosis64 54 occasional (7.5%) Occasional (29-5%) HP:0002650
72 kyphosis64 54 occasional (7.5%) Occasional (29-5%) HP:0002808
73 melanoma64 54 occasional (7.5%) Occasional (29-5%) HP:0002861
74 short stature64 54 occasional (7.5%) Occasional (29-5%) HP:0004322
75 abnormality of the retinal vasculature64 occasional (7.5%) HP:0008046
76 adenoma sebaceum64 54 occasional (7.5%) Frequent (79-30%) HP:0009720
77 renal neoplasm64 occasional (7.5%) HP:0009726
78 bone cyst64 54 occasional (7.5%) Occasional (29-5%) HP:0012062
79 ovarian neoplasm64 54 occasional (7.5%) Frequent (79-30%) HP:0100615
80 hydrocele testis64 HP:0000034
81 ovarian cyst64 HP:0000138
82 narrow mouth64 HP:0000160
83 high palate64 54 Occasional (29-5%) HP:0000218
84 hypoplasia of the maxilla64 HP:0000327
85 micrognathia64 HP:0000347
86 hypothyroidism64 HP:0000821
87 hyperthyroidism64 HP:0000836
88 thyroid adenoma64 HP:0000854
89 palmoplantar hyperkeratosis64 HP:0000972
90 subcutaneous lipoma64 54 Very frequent (99-80%) HP:0001031
91 angioid streaks of the retina64 HP:0001102
92 abnormality of the cardiovascular system64 HP:0001626
93 intention tremor64 HP:0002080
94 colonic diverticula64 HP:0002253
95 breast carcinoma64 54 Very frequent (99-80%) HP:0003002
96 hamartomatous polyposis64 54 Frequent (79-30%) HP:0004390
97 progressive macrocephaly64 HP:0004481
98 transitional cell carcinoma of the bladder64 HP:0006740
99 skin tags64 HP:0010609
100 fibroadenoma of the breast64 HP:0010619
101 varicocele64 HP:0012871
102 thyroiditis64 HP:0100646
103 abnormality of the kidney54 Occasional (29-5%)
104 abnormality of the uterus54 Occasional (29-5%)
105 macroglossia54 Frequent (79-30%)
106 abnormality of the thyroid gland54 Frequent (79-30%)
107 ataxia54 Frequent (79-30%)
108 global developmental delay54 Frequent (79-30%)
109 abnormality of the cerebellum54 Occasional (29-5%)
110 subcutaneous nodule54 Frequent (79-30%)
111 failure to thrive54 Occasional (29-5%)
112 neoplasm54 Frequent (79-30%)
113 cellular immunodeficiency54 Occasional (29-5%)
114 renal cell carcinoma54 Occasional (29-5%)
115 generalized hyperkeratosis54 Very frequent (99-80%)
116 follicular thyroid carcinoma54 Occasional (29-5%)
117 multiple cafe-au-lait spots54 Occasional (29-5%)
118 neoplasm of the skin54 Very frequent (99-80%)
119 enlarged polycystic ovaries54 Occasional (29-5%)
120 fibroma54 Frequent (79-30%)
121 lipoma54 Frequent (79-30%)
122 endometrial carcinoma54 Occasional (29-5%)
123 macule54 Very frequent (99-80%)
124 papilloma54 Very frequent (99-80%)
125 neoplasm of the central nervous system54 Occasional (29-5%)
126 papule54 Very frequent (99-80%)
127 colorectal polyposis54 Very frequent (99-80%)
128 hydrocephalus54 Frequent (79-30%)
129 hemangioma54 Very frequent (99-80%)
130 open bite54 Very frequent (99-80%)
131 epidermal nevus54 Very frequent (99-80%)
132 hand polydactyly54 Very frequent (99-80%)
133 polymicrogyria54 Very frequent (99-80%)
134 headache54 Very frequent (99-80%)
135 cranial nerve paralysis54 Very frequent (99-80%)
136 enlarged cerebellum54 Very frequent (99-80%)
137 fibroma of the breast54 Frequent (79-30%)
138 trichilemmoma54 Frequent (79-30%)
139 acrokeratosis54 Frequent (79-30%)

UMLS symptoms related to Cowden Syndrome 1:


action tremor, seizures, sciatica

GenomeRNAi Phenotypes related to Cowden Syndrome 1 according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00112-A-011.0PTEN, SMAD4
2GR00230-A-110.2AKT1, BMPR1A, EGFR, RET, STK11
3GR00210-A10.2BMPR1A, CDKN3, EGFR, PTEN, STK11
4GR00055-A-110.1AKT1, EGFR, PIK3CA, TNS1, TSC1
5GR00016-A9.8BRCA1, BRCA2, SMAD4, TSC1, TSC2
6GR00110-A-09.8BMPR1A, RET, SDHD, SMAD4, STK11, TNS1
7GR00366-A-359.5AKT1, PIK3CA, PTEN, SMAD4, TSC1
8GR00381-A-17.4AKT1, BMPR1A, BRCA1, PIK3CA, RET, SDHD

MGI Mouse Phenotypes related to Cowden Syndrome 1 according to GeneCards Suite gene sharing:

41 (show all 22)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053719.5BMPR1A, BRCA1, BRCA2, EGFR, PTEN, RET
2MP:00053709.5AKT1, EGFR, PTEN, SMAD4, STK11, TSC1
3MP:00053889.2AKT1, BMPR1A, BRCA1, EGFR, PTEN, RET
4MP:00053819.2BRCA1, BRCA2, EGFR, PTEN, RET, SEC23B
5MP:00053909.0AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA
6MP:00053699.0AKT1, BMPR1A, BRCA1, EGFR, PIK3CA, PTEN
7MP:00028738.7AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PTEN
8MP:00053678.7BRCA1, EGFR, PTEN, RET, SMAD4, STK11
9MP:00053978.7AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PTEN
10MP:00107718.7AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA
11MP:00053878.5AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA
12MP:00053808.4AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA
13MP:00020068.3AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA
14MP:00053898.2AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA
15MP:00036318.1AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA
16MP:00053798.1AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA
17MP:00053788.0AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA
18MP:00053767.9AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA
19MP:00053857.9AKT1, BMPR1A, BRCA1, EGFR, PIK3CA, PTEN
20MP:00053867.8AKT1, BMPR1A, BRCA1, BRCA2, PIK3CA, PTEN
21MP:00053847.8AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA
22MP:00107687.6AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PIK3CA

Drugs & Therapeutics for Cowden Syndrome 1

About this section

Drugs for Cowden Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
2
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
3
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 11896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
4
Doxycyclineapproved, investigational, vet_approvedPhase 4237564-25-054671203
Synonyms:
(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10597-92-9
17086-28-1 (mono-hydrate)
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)
24390-14-5
41411-66-9 (6-epimer, mono-hydrochloride)
5-Hydroxy-alpha-6-deoxytetracycline
5-hydroxy-α-6-deoxytetracycline
564-25-0
6-Deoxyoxytetracycline
6-Deoxytetracycline
6-alpha-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
69935-17-7 (mono-hydrochloride, di-hydrate)
6alpha-Deoxy-5-oxytetracycline
6alpha-deoxy-5-oxytetracycline
6α-deoxy-5-oxytetracycline
7164-70-7
7264-10-0
94088-85-4 (calcium salt (1:2))
AB08 (*Fosfatex)
AC1NQXW7
AC1NS4CW
AC1NUYS8
AC1O8PYM
Alti-Doxycycline
Anhydrous doxycycline
Apo-Doxy
Atridox
Azudoxat
BCBcMAP01_000024
BIDD:GT0146
BMY-28689
BPBio1_000951
BSPBio_000863
BSPBio_001936
BU-3839T
C06973
CHEBI:50845
CHEMBL1433
CID5281011
CID5353597
CID5463943
CID6713981
CPD001550033
D07876
DB00254
DMSC (*Fosfatex)
DOXCYCLINE ANHYDROUS
DOXY
DOXYCYCLINE CALCIUM
DOXYCYCLINE MONOHYDRATE
Deoxymykoin
DivK1c_000345
Dossiciclina
Dossiciclina [DCIT]
Doxcycline anhydrous
Doxiciclina
Doxiciclina [INN-Spanish]
Doxiciclina [Italian]
Doxitard
Doxivetin
Doxy-Caps
Doxy-Puren
Doxy-Tabs
Doxycen
Doxychel
Doxychel (TN)
Doxycin
Doxycyclin
Doxycycline (200mg/day) or Placebo
 
Doxycycline (INN)
Doxycycline (TN)
Doxycycline (anhydrous)
Doxycycline (internal use)
Doxycycline Hyclate
Doxycycline Monohydrate
Doxycycline anhydrous
Doxycycline hyclate
Doxycycline-Chinoin
Doxycyclinum
Doxycyclinum [INN-Latin]
Doxysol
Doxytec
Doxytetracycline
EINECS 209-271-1
GS-3065 (*monohydrate)
HMS2090E06
HSDB 3071
Hydramycin
IDI1_000345
Investin
Jenacyclin
KBio1_000345
KBio2_001287
KBio2_003855
KBio2_006423
KBio3_001156
KBioGR_001133
KBioSS_001287
LS-187766
LS-93868
Liviatin
Lopac0_000405
MolPort-002-507-423
Monodox
Monodox (*monohydrate)
NCGC00161602-01
NCGC00161602-03
NCGC00161602-04
NCGC00167961-01
NCGC00179395-01
NINDS_000345
NSC633557
Novo-Doxylin
Nu-Doxycycline
Oracea
Prestwick0_000852
Prestwick1_000852
Prestwick2_000852
Prestwick3_000852
Ronaxan
SAM002589932
SMP1_000107
SPBio_000246
SPBio_002784
STOCK1N-34341
Spanor
Spectrum2_000143
Spectrum3_000408
Spectrum4_000527
Spectrum5_000947
Spectrum_000807
Supracyclin
UNII-334895S862
UPCMLD-DP021
UPCMLD-DP021:001
Vibra-tabs
Vibramycin
Vibramycin (*monohydrate)
Vibramycin Novum
Vibramycine
Vibravenos
Vivox (*Hyclate)
alpha-6-Deoxy-5-hydroxytetracycline
alpha-6-Deoxyoxytetracycline
alpha-Doxycycline
doxycycline
5
VigabatrinapprovedPhase 4, Phase 22168506-86-5, 60643-86-95665
Synonyms:
( inverted question mark)-gamma-Vinyl GABA
(?)-gamma-Vinyl GABA
(R,S)-4-Amino-5-hexenoic acid
.gamma.-Vinyl-.gamma.-aminobutyric acid
.gamma.-Vinyl-GABA
4-Amino-5-hexenoic acid
4-Aminohexenoic acid
4-aminohex-5-enoic acid
60643-86-9
74046-07-4
AB00053309
AC1L1KUZ
Acid, gamma-Vinyl-gamma-Aminobutyric
Aventis Brand of Vigabatrin
BPBio1_000465
BPBio1_000925
BSPBio_000421
BSPBio_003469
Biomol-NT_000247
C07500
C6H11NO2
CHEBI:241484
CHEMBL89598
CID5665
CPP-109
D00535
D020888
DB01080
DivK1c_006760
EU-0101277
GVG
Gamma vinyl GABA
HMS1569F03
HMS2094M21
Hexenoic acid, 4-amino
Hoechst Brand of Vigabatrin
KBio1_001704
KBio2_000848
KBio2_003416
KBio2_005984
KBio3_002973
KBioSS_000848
LS-75569
Lopac0_001277
M071754
MDL 71,754
MDL 71754
 
MDL-71754
MolPort-003-666-796
NCGC00016087-03
NCGC00016087-08
NCGC00024802-02
NCGC00024802-03
NCGC00024802-04
NCGC00024802-05
NCGC00024802-06
Prestwick0_000501
Prestwick1_000501
Prestwick2_000501
Prestwick3_000501
Prestwick_837
RMI 71754
RMI-71754
RMI-71890
SPBio_002342
SPECTRUM1502036
Sabril
Sabril (TN)
Sabrilex
SpecPlus_000664
Spectrum3_001825
Spectrum_000368
V 8261
V8261_SIGMA
Vigabatrin
Vigabatrin (JAN/USAN/INN)
Vigabatrin Aventis Brand
Vigabatrin Hoechst Brand
Vigabatrin Yamanouchi Brand
Vigabatrin [USAN:BAN:INN]
Vigabatrin [USAN:INN:BAN]
Vigabatrina
Vigabatrina [Spanish]
Vigabatrine
Vigabatrine [French]
Vigabatrinum
Vigabatrinum [Latin]
Vinyl gamma-aminobutyric acid
Yamanouchi Brand of Vigabatrin
gamma Vinyl GABA
gamma Vinyl gamma Aminobutyric Acid
gamma-Vinyl GABA
gamma-Vinyl-GABA
gamma-Vinyl-gamma-Aminobutyric Acid
gamma-Vinyl-gamma-aminobutyric acid
vigabatrin
6Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
7Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13615
8Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
9Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 112770
10Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 121402
11Antiprotozoal AgentsPhase 41986
12Antiparasitic AgentsPhase 42127
13AntimalarialsPhase 41216
14Neurotransmitter AgentsPhase 4, Phase 217734
15GABA AgentsPhase 4, Phase 21622
16AnticonvulsantsPhase 4, Phase 22620
17
EthanolapprovedPhase 3204364-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
18
Verteporfinapproved, investigationalPhase 387129497-78-5
Synonyms:
Verteporfin
 
Verteporfina
Verteporfinum
Vertéporfine
19Photosensitizing AgentsPhase 3, Phase 2476
20Dermatologic AgentsPhase 3, Phase 25674
21Pharmaceutical SolutionsPhase 3, Phase 27793
22StrawberryNutraceuticalPhase 380
23
Aminolevulinic acidapprovedPhase 2157106-60-5137
Synonyms:
106-60-5
35BEC718-C970-426A-9859-BF58284C60B4
5-ALA
5-Amino-4-oxo-Pentanoate
5-Amino-4-oxo-Pentanoic acid
5-Amino-4-oxopentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Amino-Levulinate
5-Amino-Levulinic acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Aminolevulinic acid
5-amino-levulinate
5451-09-2
AC-054
AC1L18K9
AKOS003587520
ALA
ALA-PDT
Aladerm
Amino-levulinic acid
Aminolevulinate
Aminolevulinic
Aminolevulinic acid
BIDD:GT0260
BSPBio_003407
C00430
CCRIS 8958
CHEBI:17549
CHEMBL601
CID137
CPD000857229
 
D07567
DALA
DB00855
DivK1c_006954
EINECS 203-414-1
I14-10101
KBio1_001898
KBio2_002062
KBio2_004630
KBio2_007198
KBio3_002627
KBioGR_001176
KBioSS_002062
Kerastick
LMFA01100055
LS-101793
Levulinic acid, 5-amino- (8CI)
MLS001333097
MLS001333098
MolPort-001-788-423
NCGC00178086-01
Pentanoic acid, 5-amino-4-oxo- (9CI)
SAM002589919
SMR000857229
SPBio_001843
ST50819610
SpecPlus_000858
Spectrum2_001662
Spectrum3_001654
Spectrum4_000618
Spectrum5_001505
Spectrum_001582
UNII-88755TAZ87
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
delta-aminolevulinic acid
24
Propranololapproved, investigationalPhase 2216525-66-64946
Synonyms:
(+-)-Propranolol
(1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol
(R)-(+)-propranolol
(S)-(-)-PROPRANOLOL
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane
1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
13013-17-7
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI)
3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
4199-09-1
4199-10-4
525-66-6
AB00053537
AC1L1JA4
AC1Q1QBV
AC1Q1QC0
AKOS000588816
AY 64043
AY-20694
Anaprilin
Anapriline
Angilol
Apsolol
Avlocardyl
BPBio1_001040
BRD-A10070317-003-06-9
BSPBio_000944
BSPBio_002682
Bedranol
Beprane
Berkolol
Beta Neg
Beta-Neg
Beta-Propranolol
Beta-Tablinen
Beta-Timelets
Betachron
Betadren
Betalong
Bio-0732
Bio1_000367
Bio1_000856
Bio1_001345
C07407
C16H21NO2
CBDivE_006180
CCRIS 3082
CHEBI:8499
CHEMBL27
CID4946
Cardinol
Caridolol
Corpendol
D,L-Propranolol
D08443
DB00571
DL-Propranolol hydrochloride
Deralin
DivK1c_000023
Dl-Propranolol Hydrochloride
Dociton
Duranol
EINECS 208-378-0
EINECS 235-867-6
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HMS2090L21
Herzbase
ICI 45520
IDI1_000023
INDERIDE-40/25
INDERIDE-80/25
Ikopal
Inderal
Inderal La
Inderal hydrochloride
Inderalici
Inderex
Inderide
Inderol
Indobloc
InnoPranXL
 
Innopran XL
Intermigran
KBio1_000023
KBio2_002515
KBio2_005083
KBio2_007651
KBio3_001766
KBio3_001902
KBio3_002993
KBioGR_001347
KBioGR_001684
KBioGR_002515
KBioSS_002523
Kemi
Kemi S
L000679
LS-122410
LS-184129
Lopac0_000896
Migrastat
MolPort-001-794-623
NCGC00015798-07
NCGC00024690-02
NCGC00024690-03
NINDS_000023
NSC91523
Naprilin
Obsidan
Obzidan
Oposim
Oprea1_304193
PDSP1_000767
PDSP1_001607
PDSP1_001608
PDSP2_000755
PDSP2_001591
PDSP2_001592
Prano-Puren
Pranolol
Prestwick0_000952
Prestwick1_000952
Prestwick2_000952
Prestwick3_000952
Pronovan
Propanalol
Propanix
Propanolol
Propanolol [INN-Spanish]
Prophylux
Propranalol
Propranolol
Propranolol (INN)
Propranolol (TN)
Propranolol Hcl
Propranolol Hcl Intensol
Propranolol Hydrochloride
Propranolol [INN:BAN]
Propranololo
Propranololo [DCIT]
Propranololum
Propranololum [INN-Latin]
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
Racemic propranolol
Rapynogen
Reducor
Reducor Line
Reducor line
SPBio_001361
SPBio_001658
SPBio_003093
STK735510
Sagittol
Sawatal
Servanolol
Sloprolol
Spectrum2_001301
Spectrum2_001699
Spectrum3_000883
Spectrum3_001071
Spectrum4_000974
Spectrum4_001222
Spectrum5_000751
Sumial
Tesnol
UNII-9Y8NXQ24VQ
b-Propranolol
beta-Propranolol
cMAP_000071
etalong
propranolol
propranololo
β-Propranolol
25
SimvastatinapprovedPhase 1, Phase 251079902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
26RadiopharmaceuticalsPhase 2485
27Fluorodeoxyglucose F18Phase 2392
28AntimetabolitesPhase 1, Phase 211774
29Anticholesteremic AgentsPhase 1, Phase 21983
30Hypolipidemic AgentsPhase 1, Phase 22721
31Lipid Regulating AgentsPhase 1, Phase 22702
32Vasodilator AgentsPhase 23438
33Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 1, Phase 21956
34Adrenergic AgentsPhase 25140
35Antihypertensive AgentsPhase 24095
36Adrenergic AntagonistsPhase 21535
37Adrenergic beta-AntagonistsPhase 21154
38Anti-Arrhythmia AgentsPhase 22969
39Angiogenesis InhibitorsPhase 24143
40
Trastuzumabapproved, investigationalPhase 1766180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
41Protective AgentsPhase 17190
42Cariostatic AgentsPhase 1318
43FluoridesPhase 1438
44
Mentholapproved23532216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
45
Acitretinapproved3055079-83-96437841, 5284513
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid
(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
(all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
(all-e)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
13-cis-Acitretin
44707_FLUKA
44707_SIGMA
54757-46-9
55079-83-9
9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
AC-4702
AC1NR4LJ
AC1Q5T6I
Acetretin
Acitretin
Acitretin (USAN/INN)
Acitretin [USAN:INN:BAN]
Acitretina
Acitretina [Spanish]
Acitretine
Acitretine [French]
Acitretinum
Acitretinum [Latin]
BIDD:GT0617
Bio-0002
CCRIS 5534
CHEBI:50173
CHEMBL1131
CID5284513
CPD000499573
 
D02754
EINECS 259-474-4
Etretin
FT-0082892
HSDB 7187
Isoacitretin
Isoetretin
LS-96920
MLS001076667
MolPort-003-925-892
NCGC00163127-01
NCGC00163127-02
Neotigason
Retinoid etretin
Ro 10-1670
Ro 10-1670/000
Ro 13-7652
Ro-10-1670
Ro-10-1670/000
Ro-13-7652
S1368_Selleck
SAM002589973
SBB064171
SMR000499573
Soriatane
Soriatane (TN)
Soriatane, Acitretin
Spectrum5_002065
TMMP
U0279
UNII-LCH760E9T7
all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid
all-trans-Acitretin
46
Nitric Oxideapproved59910102-43-9145068
Synonyms:
(.)NO
(NO)(.)
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous Nitrate Vasodilator
Endothelium-Derived Nitric Oxide
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, Mononitrogen
Monoxide, Nitrogen
Monoxido de nitrogeno
Monoxyde d'azote
NITRIC-OXIDE
NO
NO(.)
Nitrate Vasodilator, Endogenous
Nitric Oxide, Endothelium Derived
 
Nitric Oxide, Endothelium-Derived
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
OHM 11771
Oxide, Nitric
Oxido de nitrogeno(ii)
Oxido nitrico
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoff(ii)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, Endogenous Nitrate
[NO]
endothelium-derived relaxing factor
monoxido de nitrogeno
monoxyde d'azote
nitric oxide
nitrogen monooxide
nitrogen monoxide
nitrosyl
oxido de nitrogeno(II)
oxido nitrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
47Keratolytic Agents420
48Protein C Inhibitor97
49Alpha 1-Antitrypsin99

Interventional clinical trials:

(show top 50)    (show all 62)
idNameStatusNCT IDPhase
1Rapamycin In Angiomyolipomas In Patients With Tuberous SclerosisCompletedNCT01217125Phase 4
2Doxycycline In Lymphangioleiomyomatosis (LAM)CompletedNCT00989742Phase 4
3Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) PatientsTerminatedNCT01266291Phase 4
4Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00790400Phase 3
5Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)CompletedNCT00789828Phase 3
6Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis ComplexRecruitingNCT01730209Phase 2, Phase 3
7A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)RecruitingNCT02544763Phase 3
8A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresActive, not recruitingNCT01713946Phase 3
9An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)Enrolling by invitationNCT02544750Phase 3
10Topical Everolimus in Patients With Tuberous Sclerosis ComplexNot yet recruitingNCT02860494Phase 2, Phase 3
11Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentNot yet recruitingNCT02962414Phase 3
12Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)Not yet recruitingNCT02635789Phase 3
13Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis ComplexNot yet recruitingNCT02634931Phase 3
14Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.TerminatedNCT00049959Phase 3
15Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAMUnknown statusNCT00490789Phase 2
16Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor SyndromesCompletedNCT00971789Phase 2
17A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast CancerCompletedNCT00600275Phase 1, Phase 2
18Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell CarcinomasCompletedNCT01556009Phase 2
19Rapalogues for Autism Phenotype in TSC: A Feasibility StudyCompletedNCT01929642Phase 2
20Topical Rapamycin to Erase Angiofibromas in TSCCompletedNCT01526356Phase 2
21Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)CompletedNCT01289912Phase 2
22Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00792766Phase 1, Phase 2
23RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAMCompletedNCT00457964Phase 1, Phase 2
24Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAMCompletedNCT00457808Phase 2
25Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)CompletedNCT01070316Phase 1, Phase 2
26Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis ComplexCompletedNCT00411619Phase 1, Phase 2
27Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis ComplexRecruitingNCT02849457Phase 2
28Everolimus for Cancer With TSC1 or TSC2 MutationRecruitingNCT02201212Phase 2
29A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCDRecruitingNCT02451696Phase 2
30Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockersRecruitingNCT02104011Phase 2
31Safety of Simvastatin in LAM and TSCRecruitingNCT02061397Phase 1, Phase 2
32A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous SclerosisRecruitingNCT01954693Phase 2
33A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell CarcinomasActive, not recruitingNCT01815840Phase 2
34RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome (PTEN)Not yet recruitingNCT02991807Phase 1, Phase 2
35A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast CancerCompletedNCT00620594Phase 1
36Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)CompletedNCT01031901Phase 1
37Tuberous Sclerosis Complex: Facial Angiofibroma Skin CreamCompletedNCT01853423Phase 1
38Photodynamic Therapy and Vismodegib for Multiple Basal Cell CarcinomasRecruitingNCT02639117Phase 1
39Dose Finding Trial of ARQ 092 in Children and Adults With Proteus SyndromeEnrolling by invitationNCT02594215Phase 1
40Tuberous Sclerosis Complex Natural History Study: Renal ManifestationsUnknown statusNCT00598455
41The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive DiseasesCompletedNCT00005660
42Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early ParticipantsCompletedNCT01369953
43Phenotype and Etiology of Pallister-Hall SyndromeCompletedNCT00001404
44Oligogenic Determinism of Colorectal CancerCompletedNCT01057953
45Effect of Fasting on the Size of Abdominal Lymphatic Tumors in WomenCompletedNCT00552955
46French Digestive Polyposis Cohorte Family Adenomatous Polyposis With APC and MYH Gene Mutations , Cowden's Disease With PTEN Gene Mutation, Peutz Jeghers Disease With STK 11 Gene Mutation ,juvénil Polyposis With SMAD 4 Gene Mutation , Serrated and HyperplRecruitingNCT01987518
47Natural History Study of Individuals With Autism and Germline Heterozygous PTEN MutationsRecruitingNCT02461446
48Study of Proteus Syndrome and Related Congenital DisordersRecruitingNCT00001403
49Study of Skin Tumors in Tuberous SclerosisRecruitingNCT00001975
50The Cognitive Variability in NF1 and TSC Monozygotic TwinsRecruitingNCT02436746

Search NIH Clinical Center for Cowden Syndrome 1


Cochrane evidence based reviews: hamartoma syndrome, multiple

Genetic Tests for Cowden Syndrome 1

About this section

Genetic tests related to Cowden Syndrome 1:

id Genetic test Affiliating Genes
1 Cowden Syndrome 127
2 Cowden Syndrome27 24 PTEN
3 Lhermitte-Duclos Disease27

Anatomical Context for Cowden Syndrome 1

About this section

MalaCards organs/tissues related to Cowden Syndrome 1:

36
Breast, Thyroid, Skin, Cerebellum, Brain, Tongue, Uterus

Publications for Cowden Syndrome 1

About this section

Variations for Cowden Syndrome 1

About this section

UniProtKB/Swiss-Prot genetic disease variations for Cowden Syndrome 1:

70 (show all 24)
id Symbol AA change Variation ID SNP ID
1PTENp.Ile67ArgVAR_007461
2PTENp.Tyr68HisVAR_007462rs398123317
3PTENp.His123ArgVAR_007463rs121909222
4PTENp.Cys124ArgVAR_007464rs121909223
5PTENp.Gly129GluVAR_007465rs121909218
6PTENp.Arg130LeuVAR_007467
7PTENp.Arg130GlnVAR_007468rs121909229
8PTENp.Leu112ProVAR_007807rs121909230
9PTENp.Cys136TyrVAR_007808rs786204859
10PTENp.Met35ArgVAR_008036rs121909225
11PTENp.Gly165ValVAR_008738rs786204863
12PTENp.Gly165GluVAR_008739
13PTENp.Lys289GluVAR_008741rs562015640
14PTENp.Val343GluVAR_008742
15PTENp.Phe347LeuVAR_008743
16PTENp.Arg47GlyVAR_011587rs786204855
17PTENp.Leu70ProVAR_018102rs121909226
18PTENp.Cys124SerVAR_018104
19PTENp.Cys71TyrVAR_026254
20PTENp.His93TyrVAR_026255
21PTENp.Tyr155CysVAR_026263
22PTENp.Asp331GlyVAR_026275
23PTENp.Phe341ValVAR_026276
24PTENp.Lys342AsnVAR_026277rs398123314

Clinvar genetic disease variations for Cowden Syndrome 1:

5 (show all 45)
id Gene Variation Type Significance SNP ID Assembly Location
1PTENNM_000314.6(PTEN): c.338G> T (p.Ser113Ile)SNVPathogenicrs587781254GRCh37Chr 10, 89692854: 89692854
2PTENNM_000314.6(PTEN): c.379G> A (p.Gly127Arg)SNVPathogenicrs587781255GRCh37Chr 10, 89692895: 89692895
3PTENNM_000314.6(PTEN): c.968dupA (p.Asn323Lysfs)duplicationLikely pathogenicrs587783058GRCh38Chr 10, 87961060: 87961060
4PTENNM_000314.6(PTEN): c.781C> T (p.Gln261Ter)SNVPathogenicrs730882131GRCh38Chr 10, 87957999: 87957999
5PTENNM_000314.6(PTEN): c.511C> T (p.Gln171Ter)SNVPathogenicrs786204864GRCh37Chr 10, 89711893: 89711893
6PTENNM_000314.6(PTEN): c.49C> T (p.Gln17Ter)SNVPathogenicrs786204910GRCh37Chr 10, 89624275: 89624275
7PTENNM_000314.6(PTEN): c.389delG (p.Arg130Glnfs)deletionPathogenicrs121913292GRCh37Chr 10, 89692905: 89692905
8PTENNM_000314.6(PTEN): c.71A> G (p.Asp24Gly)SNVPathogenicrs797044910GRCh37Chr 10, 89624297: 89624297
9PTENNM_000314.6(PTEN): c.437T> G (p.Leu146Ter)SNVPathogenicrs786204933GRCh37Chr 10, 89692953: 89692953
10PTENNM_000314.6(PTEN): c.987_996dupTAAAGACAAA (p.Ala333Terfs)duplicationPathogenicrs864622387GRCh38Chr 10, 87961079: 87961088
11PTENNM_000314.6(PTEN): c.845delG (p.Gly282Aspfs)deletionPathogenicrs864622451GRCh38Chr 10, 87960937: 87960937
12PTENNM_000314.6(PTEN): c.118G> T (p.Glu40Ter)SNVPathogenicrs869312778GRCh38Chr 10, 87894063: 87894063
13PTENNM_000314.6(PTEN): c.424delC (p.Arg142Glyfs)deletionPathogenicrs869312779GRCh38Chr 10, 87933183: 87933183
14PTENNM_000314.6(PTEN): c.767_768delAG (p.Glu256Valfs)deletionPathogenicrs869312780GRCh38Chr 10, 87957985: 87957986
15PTENNM_000314.6(PTEN): c.132dupC (p.Val45Argfs)duplicationPathogenicrs878853933GRCh38Chr 10, 87894077: 87894077
16PTENNM_000314.6(PTEN): c.195C> G (p.Tyr65Ter)SNVPathogenicrs878853936GRCh37Chr 10, 89685300: 89685300
17PTENNM_000314.6(PTEN): c.53delA (p.Glu18Glyfs)deletionPathogenicrs878853940GRCh38Chr 10, 87864522: 87864522
18PTENNM_000314.6(PTEN): c.545dupT (p.Leu182Phefs)duplicationPathogenicrs878853941GRCh38Chr 10, 87952170: 87952170
19PTENNM_000314.6(PTEN): c.757_758dupAT (p.Lys254Serfs)duplicationPathogenicrs878853942GRCh38Chr 10, 87957975: 87957976
20PTENNM_000314.6(PTEN): c.877G> T (p.Gly293Ter)SNVPathogenicrs878853944GRCh38Chr 10, 87960969: 87960969
21PTENNM_000314.6(PTEN): c.80-?_492+?deldeletionPathogenicChr na, -1: -1
22EGFRNM_005228.4(EGFR): c.977G> T (p.Cys326Phe)SNVPathogenicrs886037891GRCh37Chr 7, 55223610: 55223610
23CD96CD96, EXONIC BREAKPOINTundetermined variantPathogenicChr na, -1: -1
24CD96NM_198196.2(CD96): c.839C> T (p.Thr280Met)SNVPathogenicrs119477056GRCh37Chr 3, 111304209: 111304209
25PTENNM_000314.6(PTEN): c.955_958delACTT (p.Thr319Terfs)deletionPathogenicrs146650273GRCh37Chr 10, 89720804: 89720807
26PTENNM_000314.6(PTEN): c.386G> A (p.Gly129Glu)SNVPathogenicrs121909218GRCh37Chr 10, 89692902: 89692902
27PTENNM_000314.6(PTEN): c.697C> T (p.Arg233Ter)SNVPathogenicrs121909219GRCh37Chr 10, 89717672: 89717672
28PTENNM_000314.6(PTEN): c.368A> G (p.His123Arg)SNVPathogenicrs121909222GRCh37Chr 10, 89692884: 89692884
29PTENNM_000314.6(PTEN): c.370T> C (p.Cys124Arg)SNVPathogenicrs121909223GRCh37Chr 10, 89692886: 89692886
30PTENNM_000314.6(PTEN): c.347_351delACAAT (p.Asp116Alafs)deletionPathogenicrs587776666GRCh37Chr 10, 89692863: 89692867
31PTENNM_000314.6(PTEN): c.388C> T (p.Arg130Ter)SNVPathogenicrs121909224GRCh37Chr 10, 89692904: 89692904
32PTENNM_000314.6(PTEN): c.492+2T> GSNVPathogenicrs587776668GRCh37Chr 10, 89693010: 89693010
33PTENNM_000314.6(PTEN): c.696delA (p.Arg233Aspfs)deletionPathogenicrs587776669GRCh37Chr 10, 89717671: 89717671
34PTENNM_000314.6(PTEN): c.104T> G (p.Met35Arg)SNVPathogenicrs121909225GRCh37Chr 10, 89653806: 89653806
35PTENNM_000314.6(PTEN): c.209T> C (p.Leu70Pro)SNVPathogenicrs121909226GRCh37Chr 10, 89685314: 89685314
36PTENNM_000314.6(PTEN): c.389G> A (p.Arg130Gln)SNVPathogenicrs121909229GRCh37Chr 10, 89692905: 89692905
37PTENNM_000314.6(PTEN): c.1003C> T (p.Arg335Ter)SNVPathogenicrs121909231GRCh37Chr 10, 89720852: 89720852
38PTENNM_000314.6(PTEN): c.40dupA (p.Arg14Lysfs)duplicationPathogenicrs587776671GRCh38Chr 10, 87864509: 87864509
39PTENPTEN, CYS124SERundetermined variantPathogenicChr na, -1: -1
40PTENNM_000314.6(PTEN): c.802delG (p.Asp268Thrfs)deletionPathogenicrs587776672GRCh37Chr 10, 89720651: 89720651
41PTENNM_000314.6(PTEN): c.507delC (p.Ser170Valfs)deletionPathogenicrs587776673GRCh37Chr 10, 89711889: 89711889
42PTENNM_000314.6(PTEN): c.-764G> ASNVPathogenicrs587776674GRCh37Chr 10, 89623462: 89623462
43PTENNM_000314.6(PTEN): c.-861G> TSNVPathogenicrs587776675GRCh38Chr 10, 87863608: 87863608
44PTENNM_000314.6(PTEN): c.395G> T (p.Gly132Val)SNVLikely pathogenic, Pathogenicrs121909241GRCh37Chr 10, 89692911: 89692911
45PTENNM_000314.6(PTEN): c.800delA (p.Lys267Argfs)deletionPathogenicrs121913289GRCh37Chr 10, 89717775: 89717775

Expression for genes affiliated with Cowden Syndrome 1

About this section
Search GEO for disease gene expression data for Cowden Syndrome 1.

Pathways for genes affiliated with Cowden Syndrome 1

About this section

Pathways related to Cowden Syndrome 1 according to GeneCards Suite gene sharing:

(show all 40)
idSuper pathwaysScoreTop Affiliating Genes
110.0AKT1, PIK3CA, PTEN
210.0AKT1, PIK3CA, PTEN
310.0AKT1, EGFR, PIK3CA
410.0AKT1, EGFR, PIK3CA
510.0AKT1, EGFR, PIK3CA
610.0AKT1, EGFR, PIK3CA
710.0AKT1, PIK3CA, STK11
8
Show member pathways
10.0SDHB, SDHC, SDHD
9
Show member pathways
9.9AKT1, PIK3CA, RET
10
Show member pathways
9.9AKT1, EGFR, PIK3CA, PTEN
119.8BRCA1, SMAD4, TSC2
129.7AKT1, BMPR1A, PIK3CA, SMAD4
139.6AKT1, EGFR, PIK3CA, PTEN, RET
14
Show member pathways
9.6AKT1, EGFR, PIK3CA, PTEN, TSC2
15
Show member pathways
9.6AKT1, EGFR, PIK3CA, PTEN, TSC2
169.6AKT1, PTEN, TSC1, TSC2
179.6AKT1, BRCA1, EGFR, PTEN, SMAD4
18
Show member pathways
9.6AKT1, BRCA2, EGFR, PIK3CA, SMAD4
19
Show member pathways
9.6AKT1, BRCA1, EGFR, PIK3CA, SMAD4
20
Show member pathways
9.6AKT1, STK11, TSC1, TSC2
219.5SMAD4, STK11, TSC1, TSC2
22
Show member pathways
9.5AKT1, EGFR, PTEN, TSC1, TSC2
239.5AKT1, EGFR, PTEN, TSC1, TSC2
24
Show member pathways
9.5AKT1, PIK3CA, PTEN, TSC1, TSC2
259.5AKT1, PIK3CA, PTEN, TSC1, TSC2
269.5AKT1, PIK3CA, PTEN, TSC1, TSC2
27
Show member pathways
9.5AKT1, EGFR, PIK3CA, TSC1, TSC2
28
Show member pathways
9.5AKT1, EGFR, PIK3CA, PTEN, SMAD4, STK11
29
Show member pathways
9.4AKT1, PTEN, STK11, TSC1, TSC2
30
Show member pathways
9.4AKT1, PIK3CA, STK11, TSC1, TSC2
31
Show member pathways
9.4AKT1, PIK3CA, STK11, TSC1, TSC2
32
Show member pathways
9.4AKT1, EGFR, PIK3CA, PTEN, SMAD4, TSC2
33
Show member pathways
9.4AKT1, EGFR, PIK3CA, PTEN, SMAD4, TSC2
34
Show member pathways
9.2AKT1, BRCA1, PTEN, STK11, TSC1, TSC2
359.2AKT1, BRCA2, EGFR, PIK3CA, PTEN, RET
36
Show member pathways
9.1AKT1, EGFR, PIK3CA, PTEN, STK11, TSC1
379.0AKT1, BRCA1, BRCA2, EGFR, PIK3CA, PTEN
388.9AKT1, BRCA1, EGFR, PIK3CA, PTEN, STK11
39
Show member pathways
8.9AKT1, BRCA1, BRCA2, EGFR, PIK3CA, PTEN
408.4AKT1, BMPR1A, BRCA1, BRCA2, EGFR, PTEN

GO Terms for genes affiliated with Cowden Syndrome 1

About this section

Cellular components related to Cowden Syndrome 1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1respiratory chain complex IIGO:004527310.1SDHB, SDHC
2mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone)GO:000574910.1SDHB, SDHC, SDHD
3TSC1-TSC2 complexGO:00335969.9TSC1, TSC2

Biological processes related to Cowden Syndrome 1 according to GeneCards Suite gene sharing:

(show all 21)
idNameGO IDScoreTop Affiliating Genes
1cellular response to decreased oxygen levelsGO:003629410.9AKT1, PTEN
2positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycleGO:003165910.9AKT1, EGFR
3negative regulation of phosphatidylinositol 3-kinase signalingGO:001406710.8PTEN, TSC2
4chordate embryonic developmentGO:004300910.8BRCA1, BRCA2
5chromosome breakageGO:003105210.8BRCA1, BRCA2
6DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.8BRCA1, BRCA2
7ERBB2 signaling pathwayGO:003812810.7AKT1, EGFR, PIK3CA
8positive regulation of SMAD protein import into nucleusGO:006039110.7BMPR1A, SMAD4
9positive regulation of histone H3-K9 acetylationGO:200061710.7BRCA1, SMAD4
10phosphatidylinositol-mediated signalingGO:004801510.6AKT1, EGFR, PIK3CA, PTEN
11negative regulation of cell sizeGO:004579210.6AKT1, PTEN, TSC1
12regulation of phosphatidylinositol 3-kinase signalingGO:001406610.6AKT1, EGFR, PIK3CA
13response to UV-AGO:007014110.6AKT1, EGFR
14protein kinase B signalingGO:004349110.5AKT1, PIK3CA, PTEN, TSC2
15cellular response to DNA damage stimulusGO:000697410.4AKT1, BRCA1, BRCA2, STK11
16cell proliferationGO:000828310.3AKT1, BRCA2, EGFR, PTEN, SMAD4
17response to estradiolGO:003235510.2BRCA1, BRCA2, EGFR, PTEN
18protein phosphorylationGO:000646810.1AKT1, BMPR1A, PIK3CA, RET, STK11
19cell cycle arrestGO:000705010.1CDKN3, KLLN, STK11, TSC1, TSC2
20tricarboxylic acid cycleGO:000609910.0SDHB, SDHC, SDHD
21negative regulation of cell proliferationGO:00082859.8CDKN3, PTEN, SMAD4, STK11, TSC1, TSC2

Molecular functions related to Cowden Syndrome 1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1electron carrier activityGO:000905510.6SDHB, SDHC, SDHD
2nitric-oxide synthase regulator activityGO:003023510.4AKT1, EGFR
3kinase activityGO:001630110.4AKT1, EGFR, PIK3CA
4succinate dehydrogenase activityGO:000010410.3SDHC, SDHD
5ubiquinone bindingGO:004803910.1SDHB, SDHD

Sources for Cowden Syndrome 1

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet